Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Fineline Cube Jan 26, 2026
Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Fineline Cube Jan 26, 2026
Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Fineline Cube Jan 26, 2026
Company Deals Medical Device

United Imaging Healthcare Launches Medical-Grade Hearing Aid uOrigin in China

Fineline Cube Aug 5, 2024

United Imaging Healthcare Technology Co., Ltd (UIH), a leading player in the medical imaging and...

Company Deals

Bristol-Myers Squibb Terminates Partnership with Agenus on TIGIT/CD96 Bispecific Antibody

Fineline Cube Aug 5, 2024

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its decision to end its...

Company

GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance

Fineline Cube Aug 5, 2024

GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life...

Policy / Regulatory

China’s CDE Seeks Public Comment on Latest Generic Drug Reference Preparations

Fineline Cube Aug 5, 2024

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) is currently...

Company

Takeda to Slash 1,000 US Jobs as Part of Broader Restructuring Effort

Fineline Cube Aug 5, 2024

Japanese pharmaceutical giant Takeda Pharmaceuticals (TYO: 4502 / NYSE: TAK) has confirmed reports from Nikkei...

Company Drug

Yantai Dongcheng Pharmaceutical Secures NMPA Nod for PSMA-Targeted Radiotherapeutic Drug

Fineline Cube Aug 5, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China,...

Policy / Regulatory

China’s CDE Releases Draft Guidelines for CAR-T Cell Therapy Clinical Trials

Fineline Cube Aug 5, 2024

The Center for Drug Evaluation (CDE) in China has issued a draft proposal for “Technical...

Company Drug

Innovent Biologics and Sanegene Bio Commence Phase I Clinical Trial for Hypertension siRNA Drug

Fineline Cube Aug 5, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with...

Company

HutchMed Establishes Global R&D Hub in Hong Kong Science Park to Accelerate Translational Medicine

Fineline Cube Aug 5, 2024

HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced the establishment of a global research...

Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine Earns WHO Pre-Qualification Status

Fineline Cube Aug 5, 2024

China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has achieved a significant milestone with its bivalent...

Company Deals

CR Sanjiu to Acquire Significant Stake in Tasly Pharmaceuticals in a Deal Valued at $870 Million

Fineline Cube Aug 5, 2024

China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999), has announced its intention to conditionally purchase...

Company Drug

Akeso Biopharma Initiates Phase II Global Study for Ligafulimab in High-Risk MDS

Fineline Cube Aug 5, 2024

China-based Akeso Biopharma (HKG: 9926) has reached a clinical milestone with the dosing of the...

Company

Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies

Fineline Cube Aug 5, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter...

Policy / Regulatory

China’s NMPA Launches Pilot Programs in Beijing and Shanghai for Innovative Drug Approvals

Fineline Cube Aug 2, 2024

The National Medical Products Administration (NMPA) of China has given the green light to Beijing...

Policy / Regulatory

China’s State Council Unveils Guidelines to Enhance Basic Medical Insurance System

Fineline Cube Aug 2, 2024

In a bid to address the evolving healthcare needs of an aging population and a...

Company Drug

AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal

Fineline Cube Aug 2, 2024

US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition...

Company Medical Device

Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Mexico

Fineline Cube Aug 2, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in the medical device industry...

Company Drug

Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409

Fineline Cube Aug 2, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital

Fineline Cube Aug 2, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...

Company Deals

Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China

Fineline Cube Aug 2, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered...

Posts pagination

1 … 267 268 269 … 614

Recent updates

  • Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
  • Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
  • Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge
  • MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification
  • Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Medical Device

MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.